# Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma

> **NCT03892044** · PHASE1 · COMPLETED · sponsor: **David Bond, MD** · enrollment: 7 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Recurrent Diffuse Large B-Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- Richter Syndrome
- Small Lymphocytic Lymphoma
- Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma
- Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
- Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma

## Interventions

- **DRUG:** Duvelisib
- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03892044
- **Lead sponsor:** David Bond, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-05
- **Primary completion:** 2024-02-14
- **Final completion:** 2024-02-14
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2024-05-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03892044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03892044, "Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular Lymphoma". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT03892044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*